This is competing renewal of the SDRC """"""""Molecular Analysis, Modeling and Correction of Skin Diseases Core Center"""""""". This is a broad based program on the University of Colorado Anschutz Medical Campus (UCAMC) with 56 members including 22 within the Department of Dermatology. Its goal is the correction of human skin diseases by molecular techniques. The first 4 years of this Center have been highly successful: SDRC investigators in collaborative projects or in P&F projects have added $20,371,611 in new research funding to the Institutional Research Base;The P&F program itself has shown a ~35-fold return on investment during the first 4 years. Collaborations within the SDRC have resulted in 71 published papers that were greatly supported by the Research Cores. The enrichment program and the management of collaborations have created a powerful collaborative network of investigators in skin disease related research. During the next 5 year period, we will add Xiao-Xing Wang to our leadership team of David Norris, Dennis Roop and Richard Spritz. We will retain 5 Cores (Administrative Core, Molecular Genetic Analysis Core, Bioengineering Core, Morphology and Phenotyping Core, and a Flow Cytometry Core), but the services offered will be altered and enhanced based on the experience of the first 4 years of funding, and on the suggestions of the Advisory Committee. The Enrichment Program will be greatly expanded by creating: A Global Skin Diseases Research Consortium to promote international research collaborations and speed the application of new science to exciting translational research projects A Mentorship Program """"""""A New Technology Program to facilitate research within the UCAMC-SDRC and in the Global Consortium. Translational research using treatments developed by this SDRC will be greatly enhanced by addition of new members to the Clinical Investigations Team, and by the availability of a new GMP facility in close proximity to the SDRC member laboratories and clinical facilities on the AMC.
This proposal will address research areas highly relevant to NIAMS priorities: biology of skin stem cells, regenerative medicine, developmental biology of the skin and appendages, melanocyte biology, keratinocyte differentiation, immune and inflammatory skin diseases, adaptive and innate immunity, identification of the genetic basis of skin disease and development of animal models to study those diseases.
|Cao, Yu; Liu, Han; Gao, Liwei et al. (2018) Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression. Neoplasia 20:764-774|
|Mukherjee, Nabanita; Strosnider, Andrew; Vagher, Bay et al. (2018) BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis 9:907|
|Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745|
|Riching, Andrew S; Zhao, Yuanbiao; Cao, Yingqiong et al. (2018) Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes. J Vis Exp :|
|Ravindran Menon, Dinoop; Luo, Yuchun; Arcaroli, John J et al. (2018) CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res 78:6561-6574|
|Shah, Khadim; Mehmood, Sabba; Jan, Abid et al. (2017) Sequence variants in nine different genes underlying rare skin disorders in 10 consanguineous families. Int J Dermatol 56:1406-1413|
|Birlea, Stanca A; Costin, Gertrude-E; Roop, Dennis R et al. (2017) Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization. Med Res Rev 37:907-935|
|Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830|
|Gaskill, Christa F; Carrier, Erica J; Kropski, Jonathan A et al. (2017) Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. J Clin Invest 127:2262-2276|
|Mukherjee, Nabanita; Lu, Yan; Almeida, Adam et al. (2017) Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8:46801-46817|
Showing the most recent 10 out of 61 publications